{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T13:40:19Z","timestamp":1729431619193,"version":"3.27.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,20]]},"DOI":"10.7759\/cureus.71924","type":"journal-article","created":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T13:16:07Z","timestamp":1729430167000},"source":"Crossref","is-referenced-by-count":0,"title":["Fabry Disease: A Rare Mutation With Common Clinical Presentation"],"prefix":"10.7759","author":[{"given":"Mariana","family":"Certal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabete","family":"Cerqueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e1tia","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta B","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2015-103486","article-title":"Time to treatment benefit for adult patients with Fabry disease receiving agalsidase \u03b2: data from the Fabry Registry","volume":"53","author":"Ortiz A","year":"2016","unstructured":"Ortiz A, Abiose A, Bichet DG, et al.. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase \u03b2: data from the Fabry Registry. J Med Genet. 2016, 53:495-502. 10.1136\/jmedgenet-2015-103486","journal-title":"J Med Genet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S11985","article-title":"Update on role of agalsidase alfa in management of Fabry disease","volume":"5","author":"Ramaswami U","year":"2011","unstructured":"Ramaswami U. Update on role of agalsidase alfa in management of Fabry disease. Drug Des Devel Ther. 2011, 5:155-73. 10.2147\/DDDT.S11985","journal-title":"Drug Des Devel Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/gim.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang RY","year":"2007","unstructured":"Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med. 2007, 9:34-45. 10.1097\/gim.0b013e31802d8321","journal-title":"Genet Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta A","year":"2004","unstructured":"Mehta A, Ricci R, Widmer U, et al.. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004, 34:236-42. 10.1111\/j.1365-2362.2004.01309.x","journal-title":"Eur J Clin Invest"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000166000.24321.4F","article-title":"Effect of genetic modifiers on cerebral lesions in Fabry disease","volume":"64","author":"Altarescu G","year":"2005","unstructured":"Altarescu G, Moore DF, Schiffmann R. Effect of genetic modifiers on cerebral lesions in Fabry disease. Neurology. 2005, 64:2148-50. 10.1212\/01.WNL.0000166000.24321.4F","journal-title":"Neurology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055565","article-title":"Multifocal white matter lesions associated with the D313Y mutation of the \u03b1-galactosidase A gene","volume":"8","author":"Lenders M","year":"2013","unstructured":"Lenders M, Duning T, Schelleckes M, et al.. Multifocal white matter lesions associated with the D313Y mutation of the \u03b1-galactosidase A gene. PLoS One. 2013, 8:e55565. 10.1371\/journal.pone.0055565","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2007.01.053","article-title":"The cerebral vasculopathy of Fabry disease","volume":"257","author":"Moore DF","year":"2007","unstructured":"Moore DF, Kaneski CR, Askari H, Schiffmann R. The cerebral vasculopathy of Fabry disease. J Neurol Sci. 2007, 257:258-63. 10.1016\/j.jns.2007.01.053","journal-title":"J Neurol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0248-8663(10)70027-8","article-title":"Contribution of genotyping in Fabry\u2019s disease. (Article in French)","volume":"31","author":"Froissart R","year":"2010","unstructured":"Froissart R, Piraud M, Maire I. Contribution of genotyping in Fabry\u2019s disease. (Article in French). Rev Med Interne. 2010, 31:S275-8. 10.1016\/S0248-8663(10)70027-8","journal-title":"Rev Med Interne"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017098","article-title":"Fabry disease due to D313Y and novel GLA mutations","volume":"7","author":"Koulousios K","year":"2017","unstructured":"Koulousios K, Stylianou K, Pateinakis P, et al.. Fabry disease due to D313Y and novel GLA mutations. BMJ Open. 2017, 7:e017098. 10.1136\/bmjopen-2017-017098","journal-title":"BMJ Open"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry","volume":"40","author":"Sims K","year":"2009","unstructured":"Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke. 2009, 40:788-94. 10.1161\/STROKEAHA.108.526293","journal-title":"Stroke"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/294972-fabry-disease-a-rare-mutation-with-common-clinical-presentation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T13:16:08Z","timestamp":1729430168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/294972-fabry-disease-a-rare-mutation-with-common-clinical-presentation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,20]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.71924","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,20]]}}}